

Nephrology

Acute Kidney Injury	
Exam	Look for hypertension and edema (periorbital and peripheral)
Diagnostic Studies	<ul style="list-style-type: none"> • UA: <ul style="list-style-type: none"> ■ Hematuria, proteinuria, red cell casts suggests glomerulonephritis ■ Muddy brown casts suggests ATN ■ Urine eosinophils suggests acute interstitial nephritis (not a great test, may be positive even if only 1 eosinophil) • Urine electrolytes to calculate fractional excretion sodium (FENa) <ul style="list-style-type: none"> ■ $FENa = (UNa \times PCr) / (PNa \times UCr)$ ■ FENa <1% suggests prerenal; FENa >2% suggests intrarenal • Chem 10 • CBC/diff • Consider CK if history suggestive of rhabdomyolysis • Renal US to look for hydronephrosis, obstructive uropathy, renal scarring
Treatment	<ul style="list-style-type: none"> • Correct associated electrolyte issues (hyperkalemia, hyponatremia, hypocalcemia, acidosis) • Manage hypertension (see section below) • Fluid management <ul style="list-style-type: none"> ■ Small NS bolus (5-10 cc/kg) if hypovolemic or in pre-renal failure ■ Reassess volume status and continue to give small boluses until patient is euvolemic ■ Replace insensible losses plus 1:1 urine/stool output ■ Insensible losses = 300 cc/m²/day ■ $BSA = \text{square root of } [(ht \text{ cm} \times wt \text{ kg}) / 3600]$ • Indications for dialysis: AEIOU <ul style="list-style-type: none"> ■ Acidosis ■ Electrolyte anomalies refractory to medical management (hyperK/Phos) ■ Ingestions (Li, ASA) ■ Overload ■ Uremia (pericarditis, encephalopathy)

Chronic Kidney Disease	
Definition	<ul style="list-style-type: none"> • Irreversible kidney damage and reduction in kidney function; may be progressive • Requires 1 of 2 of the following (2012 KDIGO Clinical Practice Guideline); ages 2+: <ul style="list-style-type: none"> ■ GFR < 60 mL/1.73 m² for > 3 mo ■ GFR > 60 mL/1.73 m² alongside evidence of structural kidney damage or other marker of abnormal renal function (proteinuria, albuminuria, renal tubular d/o) ■ For kids <2 → GFR <1 std dev below mean = mod dysfunction, <2 std dev = severe • Severity stratified by GFR from G1 (normal, ≥90) → G2 (60-89) → G3a (45-59) → G3b (30-44) → G4 (15-29) → G5 (<15) = ESRD / dialysis-dependence
Etiology	<ul style="list-style-type: none"> • Congenital causes (renal aplasia, reflux, PKD, obstructive uropathy) in ~60% • Glomerular disease (FSGS, membranous nephropathy, MPGN, SLE nephritis, etc.) • Other: HUS, Alport syndrome, cystinosis, interstitial nephritis, tumors
Pathophysiology	Multiple possible insults leading to intraglomerular HTN and glomerular hypertrophy → nephron loss → hyperfiltration in remaining nephrons → further glomerular damage → glomerulosclerosis, proteinuria, fibrosis
Clinical Manifestations	<ul style="list-style-type: none"> • Edema + HTN • Proteinuria / hypoalbuminemia • Anemia (due to EPO deficiency) • Dyslipidemia / accelerated ASCVD • Vitamin D deficiency with secondary hyperparathyroidism • Electrolyte derangements: hyperkalemia, hyperphosphatemia, hypocalcemia, metabolic acidosis • Growth failure, delayed puberty, and intellectual disability • Complications of uremia: pericarditis, platelet dysfunction, encephalopathy

Chronic Kidney Disease	
Diagnostic Studies	<ul style="list-style-type: none"> • Chem 10 • UA w/ urine protein:Cr ratio • CBC/diff/retic + iron studies • 25-OH Vitamin D, PTH • Fasting lipid panel • If etiology uncertain: see sections on proteinuria/hematuria, consider renal U/S and bx
Management	<p>Stage G1/G2 →</p> <ul style="list-style-type: none"> • Monitor kidney function closely • Educate about nephrotoxin avoidance (NSAIDs, contrast, smoking, obesity, dehydration) • BP control w/ ACEI/ARB <ul style="list-style-type: none"> ■ ESCAPE trial - N Engl J Med. 2009;361(17):1639. Using ramipril (starting at 6 mg/m²/d and inc dose / adding other agents as needed), targeting 50th %ile BP for age, sex, and weight vs 90th %ile slowed rate of progression to ESRD <p>Stages G3 and above, add the following →</p> <ul style="list-style-type: none"> • Prepare for possibility of transplant, ideally prior to dialysis (HD vs peritoneal) • Na-restricted diet (2-3g/d) +/- diuretics (furosemide 0.5-2 mg/kg/d, HCTZ 1-3 mg/kg/d) • Management of hyperkalemia (low K diet, diuretics), acidosis (Na bicarb), hypocalcemia/hyperphosphatemia (Vitamin D, calcimimetics, phos binders) • Rx anemia to goal Hgb 10-12 g/dL w/ EPO-stimulating agents (erythropoietin alfa, darbepoetin alfa) • In pts with significant uremia, consider preoperative DDAVP to prevent bleeding

Hemolytic-Uremic Syndrome	
Definition	<ul style="list-style-type: none"> • Hemolytic Uremic Syndrome: microangiopathic hemolytic anemia + AKI + thrombocytopenia • Thrombotic Thrombocytopenic Purpura: triad of HUS + fever + neurologic changes
Etiology	<ul style="list-style-type: none"> • Principally affects children under the age of five years. • 90% due to shiga toxin; of those 70% due to <i>enterohemorrhagic E. Coli</i> • Occurs in 6-9% of EHEC infections; usually begins 5-10 days after diarrhea onset • Non-diarrheal (atypical) HUS associated can be due to <i>S. pneumo</i> infection or due to defects in the complement system (e.g., mutations in complement regulatory proteins)
Pathophysiology	<ul style="list-style-type: none"> • HUS: Shiga toxin binds to receptors in glomerular, colonic, and cerebral cells → promotes adhesion and aggregation of platelets onto endothelial cells → thrombocytopenia and RBC shearing (microangiopathic anemia); in kidney, glomerular damage • TTP: due to deficiency or immune-mediated inhibition of ADAMTS13, a metalloproteinase responsible for breakdown of vWF. No vWF cleavage → coagulation occurs at a higher rate, particularly in microvasculature → platelet consumption → thrombocytopenia and microthrombi → microangiopathic hemolytic anemia.
Clinical Manifestations	<ul style="list-style-type: none"> • Microangiopathic hemolytic anemia: jaundice, pallor, dark urine • Thrombocytopenia: petechiae, bleeding • Acute renal failure: HTN, edema • Central nervous system: seizures, coma, stroke • Cardiac: dysfunction due to ischemia, uremia, fluid overload. • Pancreas: transient DM • Liver: Hepatomegaly, increased serum transaminases • Heme: In addition to anemia and thrombocytopenia, leukocytosis is common in diarrhea-induced HUS; the prognosis is worse with increased white blood cell counts

Hemolytic-Uremic Syndrome continued on next page →